Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis

doi:10.3760/cma.j.issn.1673-422X.2018.06.006

Abstract

Abstract: Objective To investigate the correlations between peripheral absolute lymphocyte count (ALC) and clinicopathological characteristics of newly diagnosed elderly patients with multiple myeloma (MM) and its prognosis. MethodsA total of 57 elderly patients with MM were selected in Wuxi People′s Hospital Affiliated to Nanjing Medical University from January 1, 2007 to December 31, 2015. The patients were grouped as ALC≥1.3×109/L (n=24) and ALC＜1.3×109/L (n=33). The ALC and clinical characteristics of the patients were collected. The chisquare test, rank sum test, Cox regression analysis, Kaplan-Meier analysis and Logrank test were used to analyze the correlation of ALC with clinicopathological characteristics, curative effect and prognosis of elderly patients with MM. ResultsThe peripheral ALC of elderly MM patients was related to hemoglobin content (χ2=6.915, P=0.009), but it was not related to the sex, age, DurieSalmon stage, international staging system stage, creatinine content, lactate dehydrogenase content, albumin content, concentration of Ca2+, performance status and classification (all P＞0.05). There was no significant difference in efficacy between ALC≥1.3×109/L group and ALC＜1.3×109/L group (Z=0.464, P=0.642). In univariate analysis, age (RR=2.843, 95%CI: 1.3855.835, P=0.004), sex (RR=2.092, 95%CI: 1.0344.231, P=0.040), ALC (RR=3.562, 95%CI: 1.5398.244, P=0.003), hemoglobin content (RR=3.583, 95%CI: 1.08711.811, P=0.036), lactate dehydrogenase content (RR=3.192, 95%CI: 1.5806.452, P=0.001) and curative effect (RR=5.202, 95%CI: 1.18422.864, P=0.029) were related to the prognosis of patients. Multivariate analysis results revealed that age (RR=2.672, 95%CI: 1.2355.782, P=0.013) and ALC (RR=2.613, 95%CI: 1.0926.250, P=0.031) were independent predictive factors for patients with MM. KaplanMeier analysis indicated that the median overall survival of ALC≥1.3×109/L group was significantly longer than that of ALC＜1.3×109/L group (69 months vs. 24 months; χ2=10.171, P=0.001). ConclusionThe peripheral ALC in elderly patients with MM is related to hemoglobin content. ALC is an independent prognostic factor for the elderly patients with newly diagnosed MM, and has clinical value for the prognosis of MM.

Key words: Aged, Multiple myeloma, Prognosis, Absolute lymphocyte count

Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin. Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis[J]. Journal of International Oncology, 2018, 45(6): 347-351.

References

［1］ Song MK, Chung JS, Seol YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large Bcell lymphoma with RCHOP therapy［J］. Ann Oncol, 2010, 21(1): 140-144. DOI: 10.1093/annonc/mdp505. ［2］ Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes: independent prognostic value of the absolute lymphocyte count［J］. Am J Hematol, 2010, 85(3): 160-163. DOI: 10.1002/ajh.21618. ［3］ Mao J, Cheng F, Chen H, et al. Shortcourse bortezomibbased retreatment for patients with multiple myeloma who had received bortezomibthalidomidedexamethasone (VTD) as an initial therapy: a singlecenter case series［J］. Exp Ther Med, 2014, 7(4): 977-981. DOI: 10.3892/etm.2014.1496. ［4］张之南, 沈悌. 血液病诊断及疗效标准［M］. 第三版. 北京: 科学出版社, 2007: 232-235. ［5］ Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study［J］. Br J Haematol, 2008, 141(6): 792-798. DOI: 10.1111/j.1365-2141.2008.07123.x. ［6］ Song MK, Chung JS, Joo YD, et al. Clinical value of absolute lymphocyte counts before bortezomibdexamethasone therapy in relapsed multiple myeloma patients［J］. Acta Haematol, 2010, 124(1): 34-39. DOI: 10.1159/000313654. ［7］杨瑞芳, 赵志红, 张鹏. 淋巴细胞绝对计数与多发性骨髓预后的相关性分析［J］. 中国肿瘤临床, 2013, 40(20): 1224-1226. DOI: 10.3969/j.issn.1000-8179.20121876. ［8］ Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party［J］. J Clin Oncol, 2005, 23(36): 9219-9226. DOI: 10.1200/JCO.2005.03.2086. ［9］ Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma［J］. Br J Haematol, 2007, 138(5): 563-579. DOI: 10.1111/j.1365-2141.2007.06705.x. ［10］ Pellom ST, Dudimah DF, Thounaojam MC, et al. Modulatory effects of bortezomib on host immune cell functions［J］. Immunotherapy, 2015, 7(9): 1011-1022. DOI: 10.2217/imt.15.66.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[15]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.